Climb Bio Stock Market Value
| CLYM Stock | 5.63 0.01 0.18% |
| Symbol | Climb |
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Climb Bio 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Climb Bio's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Climb Bio.
| 11/24/2025 |
| 02/22/2026 |
If you would invest 0.00 in Climb Bio on November 24, 2025 and sell it all today you would earn a total of 0.00 from holding Climb Bio or generate 0.0% return on investment in Climb Bio over 90 days. Climb Bio is related to or competes with Entera Bio, Spero Therapeutics, Seres Therapeutics, Anixa Biosciences, Acumen Pharmaceuticals, Inovio Pharmaceuticals, and Actuate Therapeutics. Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. More
Climb Bio Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Climb Bio's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Climb Bio upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.73 | |||
| Information Ratio | 0.2253 | |||
| Maximum Drawdown | 42.56 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 16.99 |
Climb Bio Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Climb Bio's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Climb Bio's standard deviation. In reality, there are many statistical measures that can use Climb Bio historical prices to predict the future Climb Bio's volatility.| Risk Adjusted Performance | 0.1881 | |||
| Jensen Alpha | 1.85 | |||
| Total Risk Alpha | 1.2 | |||
| Sortino Ratio | 0.333 | |||
| Treynor Ratio | 1.08 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Climb Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Climb Bio February 22, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1881 | |||
| Market Risk Adjusted Performance | 1.09 | |||
| Mean Deviation | 6.43 | |||
| Semi Deviation | 5.13 | |||
| Downside Deviation | 5.73 | |||
| Coefficient Of Variation | 425.89 | |||
| Standard Deviation | 8.47 | |||
| Variance | 71.82 | |||
| Information Ratio | 0.2253 | |||
| Jensen Alpha | 1.85 | |||
| Total Risk Alpha | 1.2 | |||
| Sortino Ratio | 0.333 | |||
| Treynor Ratio | 1.08 | |||
| Maximum Drawdown | 42.56 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 16.99 | |||
| Downside Variance | 32.88 | |||
| Semi Variance | 26.34 | |||
| Expected Short fall | (8.14) | |||
| Skewness | 1.1 | |||
| Kurtosis | 1.68 |
Climb Bio Backtested Returns
Climb Bio is risky given 3 months investment horizon. Climb Bio secures Sharpe Ratio (or Efficiency) of 0.26, which signifies that the company had a 0.26 % return per unit of risk over the last 3 months. We have analyzed and interpolated thirty different technical indicators, which can help you to evaluate if expected returns of 2.27% are justified by taking the suggested risk. Use Climb Bio Risk Adjusted Performance of 0.1881, mean deviation of 6.43, and Downside Deviation of 5.73 to evaluate company specific risk that cannot be diversified away. Climb Bio holds a performance score of 20 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.84, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Climb Bio will likely underperform. Use Climb Bio potential upside, and the relationship between the total risk alpha and kurtosis , to analyze future returns on Climb Bio.
Auto-correlation | 0.66 |
Good predictability
Climb Bio has good predictability. Overlapping area represents the amount of predictability between Climb Bio time series from 24th of November 2025 to 8th of January 2026 and 8th of January 2026 to 22nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Climb Bio price movement. The serial correlation of 0.66 indicates that around 66.0% of current Climb Bio price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.31 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Climb Bio Correlation, Climb Bio Volatility and Climb Bio Performance module to complement your research on Climb Bio. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Climb Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.